EGFR and ALK mutation testing is suggested for patients with NSCLC, adenocarcinoma, and large-cell carcinoma by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. This evidence concerns the gene ALK and non-small cell lung carcinoma.